News summaryPsychedelic AlphaNov 2, 2026, 12:00 PM
Usona files psilocybin NDA for major depressive disorder, adding a competitor to Compass
Event: Usona Institute completed its FDA NDA submission for psilocybin for major depressive disorder. The report said Usona and Compass both have rolling review and Commissioner’s National Priority Vouchers, and Compass planned to file its treatment-resistant depression NDA in Q4 2026. Usona’s filing creates a direct psilocybin competitor.